Services

assay ready cells

Standardization of cell culture work is of ever increasing importance. Therefore, Evercyte offers services to establish assay ready cells that are frozen in formats that can directly be used for assays after thawing. Moreover, Evercyte offers services to characterize the cells for presence of cell type specific markers and functions and freedom from contaminations. Thus, reproducibility and reliability of in vitro bioassays are increased which will safe time and costs of your experiments significantly.

General information

Assay ready cells: Evercyte offers the establishment of assay ready cells either from telomerized cells (select from our broad product catalogue) or from your own proprietary cell lines    

Characterization: assay ready cells are characterized based on our customers needs; we offer functional tests as well as tests for presence of contaminations and authentication
Format of assay ready cells:
Evercyte produces the assay ready cells based on our customers needs (e.g. number of vials needed, cell number / vial)

Example – characterization of cellular functions

neo-angiogenic properties of endothelial cells  

Human umbilical vein endothelial cells HUVEC/TERT2 are characterized for neo-angiogenic properties, which are key characteristics of endothelial cells.

When seeded onto matrigel matrix the cells start formation of tubule-like structures (left). Additionally, HUVEC/TERT2 cells can be grown as 3D spheroids embedded in a collagen matrix. Treatment of the spheroids with vascular endothelial growth factor (VEGF) leads to formation of sprouts (right). These data demonstrate that telomerized HUVEC/TERT2 cells, albeit growing without limitations, show essential differentiated properties and neo-angiogenic properties.

Example – characterization of cellular functions

induction of myofibroblast differentiation

Treatment of skin fibroblasts fHDF/TERT166 cells with transforming growth factor ß (TGFß) induces expression of alpha smooth muscle actin (alpha SMA) as demonstarted by immunofluorescent staining (green: alpha SMA, blue: cell nuclei stained with DAPI). These data demonstrate the cells ability to differentiate towards myofibroblasts, which is a key event in physiological and pathological tissue repair.

Print Friendly, PDF & Email
get in contact

Related Services

characterization of primary and immortalized human cells

read more

ASC/TERT300

Adipose-derived mesenchymal stem cells for production of clinical grade exosomes

read more

MSCs for production of clinical grade extracellular vesicles

send us specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about our
EV cell factories

read more

Related Products

mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord, placenta or amniotic membrane

read more

Related Services

life span extension / immortalization and characterization of human cells from different tissues and body fluids

send specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email